These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A. Cook K; Forbes SP; Adamski K; Ma JJ; Chawla A; Garrison LP J Med Econ; 2020 May; 23(5):501-512. PubMed ID: 31971453 [No Abstract] [Full Text] [Related]
8. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. Pasi KJ; Laffan M; Rangarajan S; Robinson TM; Mitchell N; Lester W; Symington E; Madan B; Yang X; Kim B; Pierce GF; Wong WY Haemophilia; 2021 Nov; 27(6):947-956. PubMed ID: 34378280 [TBL] [Abstract][Full Text] [Related]
9. Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A. Long BR; Robinson TM; Day JRS; Yu H; Lau K; Imtiaz U; Patton KS; de Hart G; Henshaw J; Agarwal S; Vettermann C; Zoog SJ; Gupta S Mol Ther; 2024 Jul; 32(7):2052-2063. PubMed ID: 38796703 [TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1. O'Mahony B; Dunn AL; Leavitt AD; Peyvandi F; Ozelo MC; Mahlangu J; Peerlinck K; Wang JD; Lowe GC; Tan CW; Giermasz A; Tran H; Khoo TL; Cockrell E; Pepperell D; Chambost H; López Fernández MF; Kazmi R; Majerus E; Skinner MW; Klamroth R; Quinn J; Yu H; Wong WY; Robinson TM; Pipe SW J Thromb Haemost; 2023 Dec; 21(12):3450-3462. PubMed ID: 37678546 [TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment. Symington E; Rangarajan S; Lester W; Madan B; Pierce GF; Raheja P; Robinson TM; Osmond D; Russell CB; Vettermann C; Agarwal SK; Li M; Wong WY; Laffan M Haemophilia; 2024 Mar; 30(2):320-330. PubMed ID: 38317480 [TBL] [Abstract][Full Text] [Related]
12. Valoctocogene Roxaparvovec and Etranacogene Dezaparavovec: Novel Gene Therapies for Hemophilia A and B. Dougherty JA; Dougherty KM Ann Pharmacother; 2024 Aug; 58(8):834-848. PubMed ID: 37978816 [TBL] [Abstract][Full Text] [Related]
13. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B. Olasupo OO; Noronha N; Lowe MS; Ansel D; Bhatt M; Matino D Cochrane Database Syst Rev; 2024 Feb; 2(2):CD014544. PubMed ID: 38411279 [TBL] [Abstract][Full Text] [Related]
14. Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A. Symington E; Rangarajan S; Lester W; Madan B; Pierce GF; Raheja P; Millar C; Osmond D; Li M; Robinson TM Haemophilia; 2024 Jul; ():. PubMed ID: 38975624 [TBL] [Abstract][Full Text] [Related]
15. Twice Weekly Vs. Thrice Weekly Low-Dose Prophylactic Factor VIII Therapy in Children with Hemophilia A: An Open Label Randomized Trial. Gomber S; Singhal G; Dewan P; Upreti L; Sikka M J Trop Pediatr; 2022 Apr; 68(3):. PubMed ID: 35595254 [TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients. Rakmanotham A; Moonla C; Sosothikul D Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282 [TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting. Ay C; Perschy L; Rejtö J; Kaider A; Pabinger I Ann Hematol; 2020 Dec; 99(12):2763-2771. PubMed ID: 32918114 [TBL] [Abstract][Full Text] [Related]
18. Valoctocogene Roxaparvovec: First Approval. Blair HA Drugs; 2022 Sep; 82(14):1505-1510. PubMed ID: 36214970 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII. Reding MT; Ng HJ; Poulsen LH; Eyster ME; Pabinger I; Shin HJ; Walsch R; Lederman M; Wang M; Hardtke M; Michaels LA J Thromb Haemost; 2017 Mar; 15(3):411-419. PubMed ID: 27992112 [TBL] [Abstract][Full Text] [Related]